Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1947-1955

  Woo, Jong Kyu ^a   Kang, Ju Hee ^b   Jang, Yeong Su ^a   Ro, Seonggu ^c   Cho, Joong Myung ^c   Kim, Hwan Mook ^a   Lee, Sang Jin ^b   Oh, Seung Hyun ^a  

^a Gachon University   (South Korea)

^b National Cancer Center   (South Korea)

^c Crystal Genomics   (South Korea)

Author keywords

Apoptosis; Colon cancer; Non steroidal anti inflammatory drugs; TNF related apoptosis inducing ligand

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 2; CYTOKINE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; POLMACOXIB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE; TNFRSF10A PROTEIN, HUMAN; TNFRSF10C PROTEIN, HUMAN; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DEATH; CELL SURVIVAL; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SCREENING; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; M PHASE CELL CYCLE CHECKPOINT; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; INTESTINAL POLYPS; LUNG NEOPLASMS; MALE; NUDE MOUSE; PATHOLOGY; SMALL INTESTINE; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; FURANS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; INTESTINAL POLYPS; INTESTINE, SMALL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 10C; SPECIFIC PATHOGEN-FREE ORGANISMS; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924872109     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3793     Document Type: Article

References (26)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Kim MK, Kang YJ, Kim DH, et al: A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-αB in HCT116 human colon cancer cells. Int J Oncol 44: 256-264, 2014.
3. Gurpinar E, Grizzle WE and Piazza GA: NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res 20: 1104-1113, 2014.
4. Coghill AE, Newcomb PA, Chia VM, et al: Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. Br J Cancer 104: 763-768, 2011.
5. Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ and Fitzgerald GA: Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 91: 986-993, 2012.
6. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD and Srivastava RK: Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16: 1125-1138, 2005.
7. Shankar S, Ganapathy S, Chen Q and Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7: 16, 2008.
8. Shankar S and Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156, 2004.
9. Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M and Deveraux QL: Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 15: 5064-5074, 2004.
10. Liu XS, Zhu Y, Han WN, et al: Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2. Hybrid Hybridomics 22: 121-125, 2003.
11. Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193, 1975.
12. Oh SH, Woo JK, Jin Q, et al: Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 122: 5-14, 2008.
13. Oh SH, Woo JK, Yazici YD, et al: Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961, 2007.
14. Han JY, Oh SH, Morgillo F, et al: Hypoxia-inducible factor 1? and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97: 1272-1286, 2005.
15. Yamanaka Y, Shiraki K, Inoue T, et al: COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18: 41-47, 2006.
16. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F and Houghton JA: Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65: 11447-11458, 2005.
17. Cuddihy AR and O'Connell MJ: Cell-cycle responses to DNA damage in G2. Int Rev Cytol 222: 99-140, 2003.
18. Zhang XH, Zou ZQ, Xu CW, Shen YZ and Li D: Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Rep 4: 273-277, 2011.
19. Nicolini F, Burmistrova O, Marrero MT, et al: Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells. Mol Carcinog 53: 939-950, 2014.
20. Tang FY, Pai MH, Kuo YH and Wang XD: Concomitant consumption of lycopene and fish oil inhibits tumor growth and progression in a mouse xenograft model of colon cancer. Mol Nutr Food Res 56: 1520-1531, 2012.
21. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligandmediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651, 2001.
22. Xu LH, Deng CS, Zhu YQ, Liu SQ and Liu DZ: Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. World J Gastroenterol 9: 1241-1245, 2003.
23. Inoue T, Anai S, Onishi S, et al: Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol 13: 1, 2013.
24. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
25. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818, 1997.
26. Abdulghani J and El-Deiry WS: TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14: 1091-1108, 2010.